AVYCAZ Drug Patent Profile

When do Avycaz patents expire, and what generic alternatives are available?

Avycaz is a drug marketed by Abbvie and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-five patent family members in fifty-five countries.

The generic ingredient in AVYCAZ is avibactam sodium; ceftazidime. One supplier is listed for this compound. Additional details are available on the avibactam sodium; ceftazidime profile page.

DrugPatentWatch^® Generic Entry Outlook for Avycaz

Avycaz was eligible for patent challenges on February 25, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 15, 2032. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AVYCAZ

International Patents:	195
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AVYCAZ

Paragraph IV (Patent) Challenges for AVYCAZ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVYCAZ	For Injection	avibactam sodium; ceftazidime	0.5 g/2 g per vial	206494	2	2024-02-26

US Patents and Regulatory Information for AVYCAZ

AVYCAZ is protected by ten US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 8,969,566.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes	7,112,592		Y	Y
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes	8,471,025			Y
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes	8,969,566			Y
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes	7,612,087		Y

International Patents for AVYCAZ

When does loss-of-exclusivity occur for AVYCAZ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AVYCAZ around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	1614	New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
Argentina	031716	DERIVADOS DE 1-AZA Y 1,3- DIAZABICICLOETANOS Y ANALOGOS, UN PROCEDIMIENTO PARA SU PREPARACION, Y COMPOSICION FARMACEUTICA Y MEDICAMENTOS COMO ANTIBACTERIANOS
Austria	263768
Australia	2001279905

Supplementary Protection Certificates for AVYCAZ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1480644	PA2016037,C1480644	Lithuania		PRODUCT NAME: FARMACINIS MISINYS ARBA DERINYS, APIMANTIS KAIP VEIKLIUOSIUS INGREDIENTUS (1) CEFTAZIDIMA ARBA JO DRUSKA IR (2) AVIBAKTAMA ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624
1480644	C01480644/01	Switzerland		PRODUCT NAME: AVIBACTAM + CEFTAZIDIM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66890 05.06.2019
1480644	2016C/069	Belgium		PRODUCT NAME: ZAVICEFTA (COMBINAISON DE CEFTAZIDIME ET AVIBACTAM); AUTHORISATION NUMBER AND DATE: EU/1/16/1109/001 20160628
1480644	CA 2016 00059	Denmark		PRODUCT NAME: FARMACEUTISK BLANDING ELLER SAMMENSAETNING DER SOM AKTIVE BESTANDDELE DERAF, HERUNDER CEFTAZIDIMPENTAHYDRAT OG AVIBACTAMNATRIUM; REG. NO/DATE: EU/1/16/1109 20160628

AVYCAZ (Ceftazidime-avibactam) Investment and Fundamentals Analysis

Last updated: February 19, 2026

Executive Summary

AVYCAZ, the combination of ceftazidime and avibactam, is an important antibiotic for treating serious Gram-negative bacterial infections. Its patent landscape and market dynamics present both opportunities and challenges for investors. The drug targets resistant pathogens, including those producing extended-spectrum beta-lactamases (ESBLs) and carbapenemases. Key intellectual property protection remains in place, though its expiry timeline is a critical factor for future market exclusivity. Competition from newer antibiotics and evolving resistance patterns necessitate ongoing R&D and strategic market positioning.

What is AVYCAZ and Its Mechanism of Action?

AVYCAZ is a parenteral combination product approved for the treatment of specific Gram-negative bacterial infections. It combines ceftazidime, a third-generation cephalosporin antibiotic, with avibactam, a novel beta-lactamase inhibitor. This combination targets bacteria that have developed resistance to many existing antibiotics, particularly through the production of beta-lactamase enzymes.

Ceftazidime works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death. However, many Gram-negative bacteria produce beta-lactamase enzymes that can break down cephalosporins, rendering them ineffective. Avibactam is a non-beta-lactam beta-lactamase inhibitor that binds to and inactivates a broad spectrum of beta-lactamases, including ESBLs, Ambler class C (AmpC) beta-lactamases, and some carbapenemases (e.g., KPC, OXA-48-like). This mechanism protects ceftazidime from degradation, restoring its activity against resistant strains.

What Are the Approved Indications for AVYCAZ?

AVYCAZ is indicated for the treatment of adult and pediatric patients six months of age and older with infections caused by susceptible Gram-negative bacteria. These indications include:

• Complicated Intra-abdominal Infections (cIAI): In combination with metronidazole. This indication is for cases where other treatment options are inadequate.
• Complicated Urinary Tract Infections (cUTI), including Pyelonephritis: For infections caused by susceptible Gram-negative bacteria, including Pseudomonas aeruginosa.
• Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP): For infections caused by susceptible Gram-negative bacteria.

The susceptibility of the infecting Gram-negative bacteria should be confirmed. Clinical studies have demonstrated efficacy against pathogens such as Enterobacteriaceae (including ESBL producers), Pseudomonas aeruginosa, and Acinetobacter baumannii in some cases, though not all strains of carbapenem-resistant Enterobacteriaceae (CRE) are susceptible.

What is the Patent Landscape and Exclusivity for AVYCAZ?

The patent protection for AVYCAZ is multifaceted, involving patents on the active pharmaceutical ingredients (APIs), the combination product, and manufacturing processes. The primary innovator is Pfizer Inc.

• Ceftazidime: As an older antibiotic, ceftazidime's original patents have long expired. However, formulations and specific uses may have been covered by later patents.
• Avibactam: Avibactam is the key novel component providing the extended spectrum of activity. Patents covering avibactam, its synthesis, and its use in combination with beta-lactam antibiotics are crucial for AVYCAZ's market exclusivity.
• Combination Product: Patents covering the specific formulation of ceftazidime and avibactam, as well as methods of using the combination, are central to the drug's protection.

The specific expiry dates of key patents are critical for investment analysis. While detailed patent lists can be extensive and complex, general timelines for patent expiry are:

• Composition of Matter patents for avibactam and its combinations are generally expected to expire in the late 2020s or early 2030s. For instance, patents associated with avibactam as a beta-lactamase inhibitor and its use with cephalosporins have been cited with expiry dates around 2027-2030, with potential for patent term extensions.
• Method of Use patents can offer extended protection for specific indications. However, these are also subject to expiration and challenges.
• Exclusivity under regulatory frameworks: In addition to patent protection, AVYCAZ has benefited from regulatory exclusivities granted by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). For example, New Chemical Entity (NCE) exclusivities and orphan drug exclusivities, if applicable for specific rare pathogen indications, can provide additional market protection.

Key Patent Expiry Considerations: The upcoming expiry of core patents is a significant factor for potential generic competition. Manufacturers of generic versions of AVYCAZ can file Abbreviated New Drug Applications (ANDAs) once key patents expire or are successfully challenged. The timeline for this generic entry directly impacts AVYCAZ's market share and pricing power.

What is the Market Size and Growth Potential for AVYCAZ?

The market for antibiotics targeting resistant Gram-negative pathogens is substantial and growing, driven by the increasing prevalence of antimicrobial resistance (AMR).

• Market Size: The global antibiotic market is valued in the tens of billions of dollars annually. The segment for treating complicated infections caused by resistant Gram-negative bacteria is a significant sub-segment. For AVYCAZ, specific market estimates vary, but sales have reached hundreds of millions of dollars annually. For example, in 2022, Pfizer reported AVYCAZ sales of approximately $730 million.
• Growth Drivers:
  • Rising AMR: The increasing incidence of infections caused by ESBL-producing, AmpC-producing, and carbapenem-resistant Gram-negative bacteria is a primary driver.
  • Hospital-Acquired Infections (HAIs): HAIs, including cIAI, cUTI, HABP, and VABP, often involve highly resistant pathogens.
  • Limited Treatment Options: The pipeline for new antibiotics, particularly against Gram-negative resistance, has been historically challenging. This creates a demand for effective existing therapies.
  • Pediatric Approvals: Expansion to pediatric populations broadens the addressable market.

Market Challenges:

• Generic Competition: As patents expire, generic versions will enter the market, leading to price erosion and reduced market share for the originator product.
• Stewardship Programs: Antibiotic stewardship programs in hospitals aim to optimize antibiotic use, which can affect prescribing patterns and market access for newer, broader-spectrum agents.
• Emergence of New Resistance: Bacteria can develop resistance to even novel antibiotic combinations over time, requiring ongoing monitoring and development of next-generation therapies.
• Pricing and Reimbursement: The high cost of novel antibiotics can be a barrier to access in some healthcare systems, impacting market penetration.

Who are the Key Competitors to AVYCAZ?

The competitive landscape for AVYCAZ includes other antibiotics designed to combat resistant Gram-negative pathogens. These competitors can be categorized by their mechanisms of action and spectrum of activity.

Direct Competitors (Beta-Lactam/Beta-Lactamase Inhibitor Combinations):

• Meropenem-vaborbactam (VABOMERE, Remdesivir): Approved for cUTI, including pyelonephritis, caused by susceptible Gram-negative bacteria, including Enterobacteriaceae. Vaborbactam is a carbapenemase inhibitor.
• Imipenem-cilastatin-relebactam (RECARBRIO, Merck): Approved for HABP and VABP caused by susceptible Gram-negative bacteria, including Pseudomonas aeruginosa. Relebactam is a diazabicyclooctane beta-lactamase inhibitor.
• Ceftobiprole medocaril (ZEFTRA, Basilea Pharmaceutica): A broad-spectrum cephalosporin with activity against Gram-positive and Gram-negative pathogens, including some ESBL producers. It is approved for complicated skin and soft tissue infections and community-acquired pneumonia.
• Plazomicin (ZEMDRI, Seres Therapeutics): An aminoglycoside antibiotic with enhanced activity against resistant Gram-negative pathogens, including CRE, and approved for cUTI.

Other Relevant Antibiotics (Non-Beta-Lactam/Beta-Lactamase Inhibitor Combinations or Single Agents with Activity):

• Tigecycline (TIGACIL, formerly Pfizer): A glycylcycline with broad-spectrum activity, including against some CRE, used for cIAI, cSSSI, and HABP/VABP.
• Colistin (Polymyxin E): A last-resort antibiotic for multi-drug resistant Gram-negative infections, though its use is limited by nephrotoxicity and neurotoxicity.
• Newer agents targeting carbapenem resistance: Research and development continue for agents specifically targeting carbapenemases.

The competitive advantage of AVYCAZ lies in its specific spectrum of activity, including good coverage against Pseudomonas aeruginosa and many ESBL-producing organisms, along with its safety profile and established clinical data for its approved indications. However, the emergence of new resistance mechanisms and the approval of novel agents will continue to shape the competitive landscape.

What are the Regulatory and Clinical Considerations?

Regulatory Status: AVYCAZ has received marketing authorization from major regulatory bodies globally, including the U.S. FDA and the EMA. The approval pathways involved extensive clinical trials demonstrating safety and efficacy. Regulatory reviews focus on:

• Spectrum of Activity: Confirmation against relevant pathogens.
• Clinical Efficacy: Demonstrated outcomes in patient populations.
• Safety Profile: Assessment of adverse events.
• Manufacturing Quality: Ensuring consistent production and purity.

Clinical Considerations:

• Antimicrobial Stewardship: AVYCAZ is a critical treatment option, but its use is guided by antimicrobial stewardship principles to preserve its effectiveness and minimize resistance development. This includes susceptibility testing before initiation and de-escalation when appropriate.
• Resistance Monitoring: Ongoing surveillance of bacterial resistance patterns is essential to understand AVYCAZ's continued utility. This includes tracking the emergence of resistance to avibactam itself or reduced susceptibility to ceftazidime.
• Combination Therapy: For cIAI, AVYCAZ is used in combination with metronidazole to cover anaerobic pathogens.
• Labeling and Warnings: Prescribing information includes warnings regarding hypersensitivity reactions and potential for Clostridioides difficile-associated diarrhea.
• Pediatric Use: The expansion of approved indications to pediatric patients (six months and older) expands its clinical utility but requires careful dosing and monitoring specific to this age group.

What are the Financial and Investment Fundamentals?

Revenue Generation: AVYCAZ's revenue is driven by prescription volume, pricing, and market access. As a high-value, broad-spectrum antibiotic used for serious infections, it commands a premium price. Sales performance has been strong, contributing significantly to Pfizer's hospital and anti-infective portfolio.

Profitability: The profitability of AVYCAZ depends on manufacturing costs, research and development investments (for new indications or formulations), marketing and sales expenses, and the impact of any potential litigation or patent challenges. As a patented drug, it benefits from strong profit margins before patent expiry.

Investment Thesis: An investment in AVYCAZ or its manufacturer (Pfizer) is based on the enduring need for effective treatments against antibiotic-resistant infections and the drug's established market position and efficacy.

• Strengths:
  • Addresses a critical unmet medical need (AMR).
  • Broad spectrum of activity against resistant Gram-negative pathogens.
  • Established safety and efficacy profile with multiple indications.
  • Strong brand recognition within the hospital setting.
  • Significant revenue contribution.
• Weaknesses/Risks:
  • Imminent patent expiries leading to generic competition and price erosion.
  • Increasing prevalence of resistance to avibactam or ceftazidime.
  • Competition from newer antibiotic classes or combinations.
  • Potential for stricter antibiotic stewardship leading to reduced usage.
  • Pricing pressures and reimbursement challenges in certain markets.

Future Outlook: Post-patent expiry, revenue from AVYCAZ will likely decline due to generic entrants. However, the underlying demand for effective anti-infectives remains robust. Companies may explore strategies such as life cycle management, development of new formulations, or focusing on specific niche indications to extend the product's commercial life. For investors, the key consideration is the timing and impact of genericization relative to the drug's current and projected sales trajectory.

Key Takeaways

• AVYCAZ is a vital antibiotic for treating serious Gram-negative infections, combining ceftazidime with the beta-lactamase inhibitor avibactam.
• Its intellectual property protection, primarily centered around avibactam, is robust but has defined expiry timelines in the late 2020s and early 2030s.
• The market for advanced antibiotics is substantial, driven by the global rise of antimicrobial resistance.
• AVYCAZ faces competition from other broad-spectrum antibiotics, particularly newer beta-lactam/beta-lactamase inhibitor combinations.
• Regulatory approvals and ongoing clinical use are underpinned by demonstrating efficacy against resistant pathogens and managing safety profiles.
• Investment considerations hinge on the drug's current revenue contribution, patent expiry timelines, and the evolving competitive and resistance landscape.

Frequently Asked Questions

1. When is the primary patent protection for avibactam, the active component in AVYCAZ, expected to expire? Core patents covering avibactam and its use in combination with beta-lactam antibiotics are generally projected to expire around 2027-2030, with potential for extensions.

2. What are the main Gram-negative pathogens against which AVYCAZ demonstrates efficacy? AVYCAZ is effective against many Gram-negative pathogens, including Enterobacteriaceae (especially ESBL producers), Pseudomonas aeruginosa, and some Acinetobacter baumannii strains.

3. How does AVYCAZ compare to meropenem-vaborbactam in terms of indications and spectrum? While both are beta-lactam/beta-lactamase inhibitor combinations, meropenem-vaborbactam is primarily indicated for cUTI and targets carbapenemases, whereas AVYCAZ has broader indications including cIAI, cUTI, HABP, and VABP and a spectrum that includes ESBLs and certain carbapenemases.

4. What is the primary risk associated with AVYCAZ's future market exclusivity? The primary risk is the expiration of key patents, which will permit generic manufacturers to enter the market, leading to increased competition and potential price erosion.

5. Beyond patent expiry, what other factors could impact AVYCAZ's market performance? Other factors include the emergence of new resistance mechanisms to avibactam or ceftazidime, the development of novel competing antibiotics, and the impact of global antibiotic stewardship programs on prescribing patterns.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Prescribing Information for AVYCAZ. Retrieved from [FDA official website/database for drug labeling]. [2] European Medicines Agency. (n.d.). Summary of Product Characteristics for ZAVICEFTA. Retrieved from [EMA official website/database for drug labeling]. [3] Pfizer Inc. (2023). Annual Report on Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission. [4] (Various patent databases, e.g., USPTO, Espacenet, Google Patents). Specific patent numbers and expiry dates are publicly accessible and searchable. For proprietary analysis, specific patent searches for ceftazidime-avibactam combinations (e.g., US patents related to avibactam and its use with cephalosporins) would be consulted. [5] Global antibiotic market reports from reputable market research firms (e.g., Grand View Research, MarketsandMarkets, IQVIA). Specific market size data is derived from these industry reports.